Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 403,364 shares of CYTK, which is worth approximately $20.4 Million. The most recent transaction as insider was on Jun 04, 2024, when has been sold 22,500 shares (Common Stock) at a price of $48.85 per share, resulting in proceeds of $1,099,125. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 403K

1.49% 3M change

8.62% 12M change

Total Value Held $20.4 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 04 2024	SELL Open market or private sale	$1,099,125 $48.85 p/Share	22,500 Reduced 4.87%	439,145 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	61,490 Added 11.76%	461,221 Common Stock
Mar 06 2024	SELL Payment of exercise price or tax liability	$1,118,568 $66.88 p/Share	16,725 Reduced 4.02%	399,731 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$1,715,078 $67.68 p/Share	25,341 Reduced 5.74%	416,456 Common Stock
Feb 13 2024	SELL Open market or private sale	$960,624 $76.85 p/Share	12,500 Reduced 2.75%	441,797 Common Stock
Feb 13 2024	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	454,297 Common Stock
Jan 31 2024	SELL Open market or private sale	$994,624 $79.57 p/Share	12,500 Reduced 2.75%	441,797 Common Stock
Jan 31 2024	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	454,297 Common Stock
Jan 19 2024	SELL Open market or private sale	$1,017,750 $81.42 p/Share	12,500 Reduced 2.75%	441,797 Common Stock
Jan 19 2024	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	454,297 Common Stock
Jan 02 2024	SELL Open market or private sale	$1,063,500 $85.08 p/Share	12,500 Reduced 2.75%	441,797 Common Stock
Jan 02 2024	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	454,297 Common Stock
Dec 18 2023	SELL Open market or private sale	$461,875 $36.95 p/Share	12,500 Reduced 2.75%	441,797 Common Stock
Dec 18 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	454,297 Common Stock
Nov 30 2023	SELL Open market or private sale	$412,375 $32.99 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Nov 30 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Nov 15 2023	SELL Open market or private sale	$432,125 $34.57 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Nov 15 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Oct 30 2023	SELL Open market or private sale	$402,125 $32.17 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Oct 30 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Oct 16 2023	SELL Open market or private sale	$421,250 $33.7 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Oct 16 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Oct 06 2023	SELL Open market or private sale	$375,000 $30.0 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Oct 06 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Sep 13 2023	SELL Open market or private sale	$436,250 $34.9 p/Share	12,500 Reduced 2.75%	441,417 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account